A citation-based method for searching scientific literature

Shiv K Gupta, Emily J Smith, Ann C Mladek, Shulan Tian, Paul A Decker, Sani H Kizilbash, Gaspar J Kitange, Jann N Sarkaria. Front Oncol 2019
Times Cited: 28







List of co-cited articles
288 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
50

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
39

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
35

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
28

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
28


Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Catherine Hanna, Kathreena M Kurian, Karin Williams, Colin Watts, Alan Jackson, Ross Carruthers, Karen Strathdee, Garth Cruickshank, Laurence Dunn, Sara Erridge,[...]. Neuro Oncol 2020
14
50

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
21

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
21

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.
Ben Fulton, Susan C Short, Allan James, Stefan Nowicki, Catherine McBain, Sarah Jefferies, Caroline Kelly, Jon Stobo, Anna Morris, Aoife Williamson,[...]. Clin Transl Radiat Oncol 2017
31
21

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Shiv K Gupta, Sani H Kizilbash, Brett L Carlson, Ann C Mladek, Felix Boakye-Agyeman, Katrina K Bakken, Jenny L Pokorny, Mark A Schroeder, Paul A Decker, Ling Cen,[...]. J Natl Cancer Inst 2015
53
21

MGMT testing--the challenges for biomarker-based glioma treatment.
Wolfgang Wick, Michael Weller, Martin van den Bent, Marc Sanson, Markus Weiler, Andreas von Deimling, Christoph Plass, Monika Hegi, Michael Platten, Guido Reifenberger. Nat Rev Neurol 2014
266
21

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
21

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Jann N Sarkaria, Leland S Hu, Ian F Parney, Deanna H Pafundi, Debra H Brinkmann, Nadia N Laack, Caterina Giannini, Terence C Burns, Sani H Kizilbash, Janice K Laramy,[...]. Neuro Oncol 2018
157
17

The definition of primary and secondary glioblastoma.
Hiroko Ohgaki, Paul Kleihues. Clin Cancer Res 2013
529
17

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
17

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
17

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Paul Lesueur, Justine Lequesne, Jean-Michel Grellard, Audrey Dugué, Elodie Coquan, Pierre-Emmanuel Brachet, Julien Geffrelot, William Kao, Evelyne Emery, David Hassanein Berro,[...]. BMC Cancer 2019
31
17

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy, Jing Wang. Oncotarget 2018
40
17

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017
224
17

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
Shideng Bao, Qiulian Wu, Roger E McLendon, Yueling Hao, Qing Shi, Anita B Hjelmeland, Mark W Dewhirst, Darell D Bigner, Jeremy N Rich. Nature 2006
17

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, Mara V A Koerner, Hiroaki Wakimoto, Daniel P Cahill. Clin Cancer Res 2020
21
23

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
14

Temozolomide: mechanisms of action, repair and resistance.
Jihong Zhang, Malcolm F G Stevens, Tracey D Bradshaw. Curr Mol Pharmacol 2012
334
14

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Stephen Yip, Jiangyong Miao, Daniel P Cahill, A John Iafrate, Ken Aldape, Catherine L Nutt, David N Louis. Clin Cancer Res 2009
248
14

The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Timothy A Yap, Ruth Plummer, Nilofer S Azad, Thomas Helleday. Am Soc Clin Oncol Educ Book 2019
63
14

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Olivier L Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Antoine F Carpentier, Khe Hoang-Xuan, Petr Kavan, Dana Cernea,[...]. N Engl J Med 2014
14

Clonal evolution of glioblastoma under therapy.
Jiguang Wang, Emanuela Cazzato, Erik Ladewig, Veronique Frattini, Daniel I S Rosenbloom, Sakellarios Zairis, Francesco Abate, Zhaoqi Liu, Oliver Elliott, Yong-Jae Shin,[...]. Nat Genet 2016
318
14

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
Cyril Neftel, Julie Laffy, Mariella G Filbin, Toshiro Hara, Marni E Shore, Gilbert J Rahme, Alyssa R Richman, Dana Silverbush, McKenzie L Shaw, Christine M Hebert,[...]. Cell 2019
309
14

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
Anoop P Patel, Itay Tirosh, John J Trombetta, Alex K Shalek, Shawn M Gillespie, Hiroaki Wakimoto, Daniel P Cahill, Brian V Nahed, William T Curry, Robert L Martuza,[...]. Science 2014
14

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J van den Bent, Martin J B Taphoorn, Jonathan Steuve, Alba A Brandes, Marie-France Hamou, Antje Wick,[...]. Clin Cancer Res 2016
67
14

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
H Ian Robins, Peixin Zhang, Mark R Gilbert, Arnab Chakravarti, John F de Groot, Sean A Grimm, Fen Wang, Frank S Lieberman, Andra Krauze, Andy M Trotti,[...]. J Neurooncol 2016
30
14

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Sani H Kizilbash, Shiv K Gupta, Kenneth Chang, Ryo Kawashima, Karen E Parrish, Brett L Carlson, Katrina K Bakken, Ann C Mladek, Mark A Schroeder, Paul A Decker,[...]. Mol Cancer Ther 2017
24
16

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Jörg Felsberg, Niklas Thon, Sabina Eigenbrod, Bettina Hentschel, Michael C Sabel, Manfred Westphal, Gabriele Schackert, Friedrich Wilhelm Kreth, Torsten Pietsch, Markus Löffler,[...]. Int J Cancer 2011
194
14

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
M Esteller, J Garcia-Foncillas, E Andion, S N Goodman, O F Hidalgo, V Vanaclocha, S B Baylin, J G Herman. N Engl J Med 2000
14

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Ian Hickson, Yan Zhao, Caroline J Richardson, Sharon J Green, Niall M B Martin, Alisdair I Orr, Philip M Reaper, Stephen P Jackson, Nicola J Curtin, Graeme C M Smith. Cancer Res 2004
910
10

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
Eric Bouffet, Valérie Larouche, Brittany B Campbell, Daniele Merico, Richard de Borja, Melyssa Aronson, Carol Durno, Joerg Krueger, Vanja Cabric, Vijay Ramaswamy,[...]. J Clin Oncol 2016
428
10


Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells.
Ross D Carruthers, Shafiq U Ahmed, Shaliny Ramachandran, Karen Strathdee, Kathreena M Kurian, Ann Hedley, Natividad Gomez-Roman, Gabriela Kalna, Mathew Neilson, Lesley Gilmour,[...]. Cancer Res 2018
46
10

PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites.
Jean-François Haince, Darin McDonald, Amélie Rodrigue, Ugo Déry, Jean-Yves Masson, Michael J Hendzel, Guy G Poirier. J Biol Chem 2008
328
10

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma.
Koji Yoshimoto, Masahiro Mizoguchi, Nobuhiro Hata, Hideki Murata, Ryusuke Hatae, Toshiyuki Amano, Akira Nakamizo, Tomio Sasaki. Front Oncol 2012
56
10

Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation.
Paul Lesueur, François Chevalier, Elias A El-Habr, Marie-Pierre Junier, Hervé Chneiweiss, Laurent Castera, Etienne Müller, Dinu Stefan, Yannick Saintigny. Sci Rep 2018
34
10

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.
Toni Rose Jue, Kyoko Nozue, Ashleigh J Lester, Swapna Joshi, Lisette B W Schroder, Shane P Whittaker, Sheri Nixdorf, Robert W Rapkins, Mustafa Khasraw, Kerrie L McDonald. J Transl Med 2017
18
16

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Shiv K Gupta, Ann C Mladek, Brett L Carlson, Felix Boakye-Agyeman, Katrina K Bakken, Sani H Kizilbash, Mark A Schroeder, Joel Reid, Jann N Sarkaria. Clin Cancer Res 2014
41
10

Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Quanye Sun, Chunying Pei, Qiuyuan Li, Tianxiu Dong, Yucui Dong, Wenjing Xing, Peng Zhou, Yujiao Gong, Ziqi Zhen, Yifan Gao,[...]. Biochem Biophys Res Commun 2018
11
27

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Chris Hunter, Raffaella Smith, Daniel P Cahill, Philip Stephens, Claire Stevens, Jon Teague, Chris Greenman, Sarah Edkins, Graham Bignell, Helen Davies,[...]. Cancer Res 2006
289
10

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Qianghu Wang, Baoli Hu, Xin Hu, Hoon Kim, Massimo Squatrito, Lisa Scarpace, Ana C deCarvalho, Sali Lyu, Pengping Li, Yan Li,[...]. Cancer Cell 2017
499
10

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
10

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
Heidi S Phillips, Samir Kharbanda, Ruihuan Chen, William F Forrest, Robert H Soriano, Thomas D Wu, Anjan Misra, Janice M Nigro, Howard Colman, Liliana Soroceanu,[...]. Cancer Cell 2006
10

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Lucio Tentori, Lucia Ricci-Vitiani, Alessia Muzi, Fabio Ciccarone, Federica Pelacchi, Roberta Calabrese, Daniele Runci, Roberto Pallini, Paola Caiafa, Grazia Graziani. BMC Cancer 2014
44
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.